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Compared to other organs, the eyes are relatively in-
frequent sites of metastasis. In a landmark case series, Ferry
and Font described 227 cases of carcinoma metastatic to
the eyes.1,2 Among these cases, only 28 (12%) were orbital
metastases, most frequently from tumors of the breast, lung,
and genitourinary tract; in this series, the diagnosis of or-
bital metastasis preceded the diagnosis of the primary
tumor in 61% of cases.2 Metastases represent from 1% to
13% of orbital tumors, the rest being accounted for by pri-
mary tumors. We present the case of a patient in whom or-
bital metastasis was the first manifestation of cancer.
CASE REPORT
A 57-year-old man presented with a 6-month history of
orbital swelling in December 2003. He complained of pro-
gressive bulging of the temporal aspect of his right orbit,
but postponed his medical visit for approximately 6 months.
On presentation, the patient had a temporal nodule, prop-
tosis, and mild visual discomfort, but was otherwise asymp-
tomatic. A computed tomography (CT) scan showed an or-
bital soft tissue mass leading to bone erosion and intracra-
nial invasion (Figure 1). Percutaneous incisional biopsy of
the lesion showed a neoplasm with a pseudoglandular,
trabecular pattern of polygonal cells, prominent nucleoli,
vesicular nuclei, and bile plugs, consistent with hepatocel-
lular carcinoma (Figure 2, Panel A). On immunohistochem-
istry, the tumor cells stained positive for a low-molecular-
weight cytokeratin (CAM 5.2), and carcinoembryonic an-
tigen (CEA) staining outlined the bile canaliculi (Figure
2, Panels B and C). A CT scan of the liver showed a focal
perfusion abnormality in the left lobe (Figure 3, arrow). The
serum level of alpha-fetoprotein was normal. Hepatitis-B
surface antigen was detected in the serum, and antihepatitis
C virus antibodies were negative. The patient initially re-
fused treatment and was lost to follow up for several
months. He presented again in July 2004, with massive
growth of the orbital tumor since diagnosis (Figure 4). He
had progressive visual loss, but no significant pain. Given
the impossibility of effective surgical or radiotherapeutic
palliation and the progressive destruction of adjacent tis-
sues, he received systemic treatment with megestrol acetate
and gemcitabine. One month after treatment initiation, he
Figure 1. Computed tomography at the level of the eyes shows an orbital
soft tissue mass leading to bone erosion and intracranial invasion.
Figure 2, Panel A. Biopsy of orbital mass shows a neoplasm with
pseudoglandular, trabecular pattern of polygonal cells, prominent nucleoli,
vesicular nuclei, and bile plugs (hematoxylin and eosin staining;
magnification, 400x).
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reported symptomatic improvement and had an increased
performance status, but had no objective tumor response.
Chemotherapy was discontinued after 4 cycles. He even-
tually experienced progression of the orbital lesion, and
died in March 2005, 15 months after initial presentation.
DISCUSSION
Orbital metastasis is a clinically infrequent phenom-
enon, accounting for approximately 1 in 8 of the tumors
that metastasize to the ocular structures.1 In some of the
largest Western series reported to date, the most common
primary tumors leading to orbital metastases were breast,
lung, and prostate cancers. In most of these series, no cases
of hepatocellular carcinoma were described. In contrast, a
recent review from Japan has shown that hepatocellular car-
cinoma is the third most frequent cause of orbital metasta-
sis in that country, after lung and breast cancer.4 In Japan,
hepatocellular carcinoma is among the leading causes of
cancer incidence and death. Although liver cancer is a ma-
jor health problem in Japan, China, South East Asia, and
sub-Saharan Africa, Brazil is a country with an intermedi-
ate age-standardized incidence rate5 and in which the dis-
ease is not among the 10 most frequent tumor types.6
Other case reports of hepatocellular carcinoma meta-
static to the orbit have appeared in the Western literature
in the past 2 decades and have been reviewed more re-
cently.7 Most of these cases were reported in ophthalmol-
Figure 2, Panel B. Immunohistochemistry shows positive staining of the
tumor cells with a low-molecular-weight cytokeratin, CAM 5.2
(magnification, 400x).
Figure 2, Panel C. Immunohistochemistry shows positive staining of the
tumor cells and bile canaliculi with carcinoembryonic antigen
(magnification, 400x).
Figure 3. Computed tomography of the abdomen shows a focal perfusion
abnormality in the left lobe of the liver (arrow).
Figure 4. Massive growth of the orbital mass is shown on computed
tomography (top) and clinically (bottom).
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ogy journals of the US and Europe. As for our patient, in
many of these case reports, the orbital metastasis was of-
ten the first manifestation of hepatocellular carcinoma.8,9
Likewise, in the Japanese series of 18 cases, approximately
80% of the patients had orbital metastasis as the first sign
of liver cancer.4 It is not always clear whether clinically
apparent orbital metastases from hepatocellular carcinoma
represent local extension from an osseous lesion or meta-
static deposits in the soft tissues of the orbit.4 Proptosis,
visual disturbance, and ocular pain are the most frequent
clinical findings.4,7 There seems to be no lateral prepon-
derance for orbital involvement by hepatocellular carci-
noma, but the lesion was consistently unilateral in the case
reports and series.
The pathological diagnosis of an orbital metastasis from
hepatocellular carcinoma is usually straightforward and com-
monly guides the investigation toward the primary tumor.
The typical appearance is that of a trabecular pattern asso-
ciated with polygonal cells that have an acidophilic cyto-
plasm, large round or oval nuclei, and prominent nucleoli.
Immunohistochemistry may be helpful and typically dem-
onstrates staining of tumor cells with CAM 5.2, and of bile
canaliculi with polyclonal CEA. Although serum levels of
alpha-fetoprotein are elevated in up to 90% of patients, ex-
pression on immunohistochemistry is only found in 30% to
50% of the primary tumors.7,10 Interestingly, other cases of
orbital metastases with normal serum levels9 or negative tis-
sue expression of alpha-fetoprotein have been reported.7
Treatment for metastatic hepatocellular carcinoma is of
limited efficacy. In the cases of orbital metastases from
hepatocellular carcinoma reported to date, focal radio-
therapy has been the most frequent treatment modality. Al-
though surgery has typically been limited to diagnostic pur-
poses, an occasional patient may derive benefit from local
excision. Some patients have also been treated with sys-
temic chemotherapy. Currently, no chemotherapeutic agent
may be considered standard, and hormonal agents such as
megestrol acetate and tamoxifen may provide palliative
benefit to some patients. In our patient, symptomatic im-
provement followed the administration of megestrol acetate
and gemcitabine, but we were uncertain as to the relative
contribution of these agents. The average survival of pa-
tients with orbital metastases from hepatocellular carci-
noma has been reported as 10.4 months,4 and often depends
on the disease status elsewhere in the body. Our report il-
lustrates the possibility of massive growth of an untreated
orbital metastasis of hepatocellular carcinoma, and reminds
clinicians of this possible cause of orbital tumor.
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